Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04832932Unknown

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

Role: lead

NCT03582826Not ApplicableCompleted

Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions

Role: lead

NCT02683876Completed

Exploratory Study of Relationships Between Malodor and Urine Metabolomics

Role: lead

NCT03451994Completed

Exploratory Study of Volatile Organic Compounds in Alveolar Breath

Role: lead

NCT02692495Completed

Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis

Role: lead

All 5 trials loaded